Risk Analysis of Respiratory Syncytial Virus Among Infants in the United States by Birth Month.

Jason R Gantenberg Robertus van AalstMonika Reddy BhumaBrendan LimoneDavid DiakunDavid M SmithChristopher B Nelson Angela M Bengtson Sandra S Chaves William V La ViaChristopher RizzoDavid A Savitz Andrew R Zullo

Published in: Journal of the Pediatric Infectious Diseases Society (2024)

Our data support recent national recommendations for the use of nirsevimab in the USA. For infants born at the tail end of an RSV season who do not receive nirsevimab, a dose administered prior to the onset of their second RSV season could reduce the incidence of outpatient- and ED-related events.

Keyphrases

respiratory syncytial virus
gestational age
emergency department
risk factors
quality improvement
electronic health record
big data
clinical practice
low birth weight
preterm birth
deep learning
breast cancer risk